Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. Elucidating the evolution of NEPC and the resistance...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhe Zhu, Wenjing Xuan, Chaohui Wang, Chancan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	long noncoding RNA enzalutamide enzalutamide resistance neuroendocrine prostate cancer AR prostate cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1481777/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
by: Sung Hee Lim, et al.
Published: (2024-03-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
by: Xiannan Meng, et al.
Published: (2025-01-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

GG-NER’s role in androgen receptor signaling inhibitor response for advanced prostate cancer
by: Chuanfan Zhong, et al.
Published: (2024-12-01)

Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer
by: Xinwen Wang, et al.
Published: (2025-01-01)

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
by: Sihyeon Kim, et al.
Published: (2023-11-01)

ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
by: Agathe Bessot, et al.
Published: (2025-02-01)

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis
by: Nobuaki Matsubara, et al.
Published: (2025-01-01)

Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study
by: Takashi Kawahara, et al.
Published: (2025-01-01)

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer
by: Zoe R. Maylin, et al.
Published: (2024-12-01)

Co-modulation of a circular form of PCDH11Y during neuroendocrine differentiation of prostate cancer
by: Giovanni Pecoraro, et al.
Published: (2025-02-01)

Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
by: Nicole M. Naranjo, et al.
Published: (2024-12-01)

Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
by: Qiang Dang, et al.
Published: (2015-08-01)

CHROMOGRANIN-A IN THE DIAGNOSIS OF PROSTATE CANCER
by: A. V. Sivkov, et al.
Published: (2015-04-01)

A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review
by: Weizhe Han, et al.
Published: (2025-01-01)

The miRNAs 203a/210‐3p/5001‐5p regulate the androgen/androgen receptor/YAP‐induced migration in prostate cancer cells
by: Chieh Huo, et al.
Published: (2024-08-01)

The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
by: Abhijit Parolia, et al.
Published: (2019-05-01)

Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review
by: Xin Fei, et al.
Published: (2024-12-01)

Transcriptional landscape and predictive potential of long noncoding RNAs in peritoneal recurrence of gastric cancer
by: Xiao-Xia Cai, et al.
Published: (2024-12-01)

The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations
by: Pushkar Malakar, et al.
Published: (2024-12-01)

Construction of a potentially functional long noncoding RNA-microRNA-mRNA network in diabetic cardiomyopathy
by: Qiwen Cao, et al.
Published: (2024-12-01)

The correlation between the expression of androgen receptor splice variant-7 (AR-V7) protein with the time of occurrence of castration-resistant prostate cancer and overall survival in prostate cancer in Indonesian population
by: Indrawarman Soerohardjo, et al.
Published: (2025-02-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
by: Xiaoying Tang, et al.
Published: (2025-02-01)

Adeno-associated virus mediated artificial circular RNA for triggering cancer immunotherapy to treat prostate cancer
by: Chujin Ye, et al.
Published: (2025-01-01)

Potential clinical application of the cancer antigen CA‑62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate‑specific antigen
by: Zh. R. Cherkasova, et al.
Published: (2023-03-01)

The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores
by: Tzu-Heng Huang, et al.
Published: (2025-02-01)

Integrated single-cell transcriptomic analyses identify a novel lineage plasticity-related cancer cell type involved in prostate cancer progressionResearch in context
by: Faming Zhao, et al.
Published: (2024-11-01)

Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men
by: Abudu EK, et al.
Published: (2025-01-01)

Long noncoding RNAs and metabolic memory associated with continued progression of diabetic retinopathy
by: Jay Kumar, et al.
Published: (2024-11-01)

Editorial: Prostate cancer research: tools, cancer cell types, molecular targets
by: Hung-Ming Lam, et al.
Published: (2025-02-01)

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance
by: Caihong Li, et al.
Published: (2025-02-01)

Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review
by: Jae Sung Yoo, et al.
Published: (2025-01-01)

Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4-10 ng/ml)
by: Abdulsattar J. Ali, et al.
Published: (2020-12-01)

LNRRIL6, a novel long noncoding RNA, protects colorectal cancer cells by activating the IL‐6–STAT3 pathway
by: Jiaxing Wang, et al.
Published: (2019-11-01)

Giant sarcoma of the prostate stroma: Clinical, radiological and histopathological analysis of a rare prostatic cancer
by: Alan de Jesus Martinez Salas, et al.
Published: (2024-11-01)

<i>SVALKA</i>: A Long Noncoding Cis-Natural Antisense RNA That Plays a Role in the Regulation of the Cold Response of <i>Arabidopsis thaliana</i>
by: Nicholas M. Kiger, et al.
Published: (2024-11-01)

Prostatitis, benign prostatic hyperplasia, and prostate cancer: a bidirectional Mendelian randomization study and clinical implications for these patients’ populations
by: Yi Wang, et al.
Published: (2024-12-01)

COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY
by: M. E. Topuzov, et al.
Published: (2015-10-01)